Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain bleed breakthrough? drug may stop deadly vessel spasms

NCT ID NCT06352593

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a sedative called dexmedetomidine during a procedure to fix a brain aneurysm can prevent dangerous blood vessel spasms. 90 adults who had a brain bleed from a ruptured aneurysm took part. The goal was to see if the drug reduces complications and improves recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Apr 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged \>18 years. * Both sexes. * American Society of Anesthesiologists (ASA) I-III * Unruptured subarachnoid hemorrhage (SAH) confirmed by digital subtraction catheter angiography (DSA) undergoing endovascular intervention with general anesthesia. Exclusion Criteria: * Subarachnoid hemorrhage (SAH) from a lesion other than a ruptured saccular aneurysm. * Intraventricular or intracerebral blood in the absence of localized thick or diffuse Subarachnoid hemorrhage (SAH). * No or localized thin subarachnoid hemorrhage (SAH) on computed tomography (CT). * Cerebral vasospasm on admission digital subtraction catheter angiography (DSA). * Hypotension (systolic blood pressure 90 mm Hg) refractory to fluid therapy. * Neurogenic pulmonary edema. * Cardiac failure requiring inotropic support. * Severe or unstable concomitant condition or disease or chronic condition. * Kidney and/or liver disease. * Prior cerebral damage on computed tomography (CT) scan such as stroke (\>2 cm maximum diameter). * Pregnancy. * Traumatic brain injury. * Previously treated cerebral aneurysm. * Arterial venous malformation. * Pre-existing cerebrovascular disorder that will affect diagnosis and evaluation of Subarachnoid hemorrhage (SAH). * Ischemic heart disease or second or third-degree atrioventricular block. * Long-term abuse of alcohol, opioids, or sedative-hypnotic drugs. * Obesity (body mass index \[BMI\] \>30 kg/m2).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneurysmal subarachnoid hemorrhage Dexmedetomidine Endovascular Infusion

Contacts and locations

Locations

  • Tanta University Hospitals

    Tanta, ElGharbia, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.